Zymeworks Inc.
Symbol: ZYME (NASDAQ)
17.67
▼ (-1.45%) -0.260
Company Description:
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Key Stats
- Today's Open: $17.92
- Today's High: $18.136
- Today's Low: $17.43
- Today's Volume: 858.79K
- Yesterday Close: $17.93
- Yesterday High: $18.455
- Yesterday Low: $17.92
- Yesterday Volume: 613.03K
- Last Min Volume: 10
- Last Min High: $17.67
- Last Min Low: $17.67
- Last Min VWAP: $17.67
Company Profile
- Name: Zymeworks Inc.
- Website: https://www.zymeworks.com
- Listed Date: 2017-04-28
- Location: MIDDLETOWN, DE
- Market Status: Active
- CIK Number: 0001937653
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.36B
- Round Lot: 100
- Outstanding Shares: 75.74M
- Asset Type: CS
RECENT FILINGS FOR ZYME
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-02 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 4 | View |
| 2025-08-12 | 4 | View |
| 2025-08-12 | 3 | View |
| 2025-08-12 | 3 | View |
| 2025-08-11 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-27 | SCHEDULE 13D | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 8-K | View |
| 2025-05-30 | 8-K | View |
| 2025-05-19 | 4 | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-05-07 | SCHEDULE 13G/A | View |
| 2025-04-18 | 4 | View |
| 2025-04-08 | SCHEDULE 13D/A | View |
Latest News on ZYME